Abstract Library

#2797 Assessment of Quality of Life in Patients with Neuroendocrine Tumours: Results of a Systematic Literature Review

Introduction: Health related quality of life (HRQoL) is increasingly important as a concept reflecting the patients’ perspective in conjunction with the disease presentation severity and treatment. Understanding the impact of treatment on neuroendocrine tumour (NET) patients’ HRQoL is paramount given the nature of the disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fountain D, Leeuwenkamp O, Watson C, Longworth L,

Keywords: Gastro-entero-pancreatic neuroendocrine tumours, Quality of Life, 177Lu-Dotatate, EORTC QLQ-C30,

#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Fahlenkamp U, Prasad V, Pavel M, Geisel D,

Keywords: magnetic resonance, hepatocyte specific, liver specific, gadoxetate, gadoxetic acid, neuroendocrine, staging, shuttle, large bore, whole abdomen, pelvis, extrahepatic evaluation,

#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?

Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Kamp K

Authors: Kamp K, Adrichem van R, Vandamme T, Peeters M, Feelders R,

Keywords: GEP-NET, CgA, prognosis,

#1517 Additional Value for Urinary 5-Hydroxyindoleacetic Acid as Prognostic Marker in Neuroendocrine Tumors?

Introduction: 5-Hydroxyindoleacetic Acid (5-HIAA) is of value for diagnosis of NETs and correlates with severity of carcinoid syndrome. However its value for determining prognosis is uncertain, particularly in combination with other biomarkers

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Zandee W

Authors: Zandee W, Kamp K, Van Adrichem R, Feelders R, De Herder W,

Keywords: prognosis 5-HIAA,

#1496 Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-differentiated Neuroendocrine Tumors Resistant to Prior Treatments

Introduction: Alternating treatment with sunitinib and everolimus, has been shown to be efficacious in renal cell carcinoma

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Angelousi A, Kampel K, O'Toole D, Kaltsatoy M, Boutzios G,

Keywords: everolimus, sunitinib, pancreatic NETs,